FIELD: biotechnology.
SUBSTANCE: to consideration is presented a vaccine composition used for performing preventive, metaphylactic or therapeutic treatment of infection caused by Streptococcus suis, in swine and in humans, containing an effective amount of at least one protein or at least one vector, and at least a pharmaceutical carrier, diluent or adjuvant.
EFFECT: this vaccine composition is used in preventive, metaphylactic or therapeutic treatment of infections caused by Streptococcus suis in swine or humans.
16 cl, 6 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN p53 | 2020 |
|
RU2830061C2 |
| NGF ANTAGONISTS FOR MEDICAL USE | 2020 |
|
RU2829812C2 |
| COMPOSITIONS AND METHODS OF GENE EDITING | 2019 |
|
RU2804665C2 |
| IL4 RECEPTOR ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2019 |
|
RU2837141C2 |
| MUTANT NITRILE HYDRATASE, NUCLEIC ACID WHICH ENCODES SAID MUTANT NITRILE HYDRATASE, EXPRESSION VECTOR AND TRANSFORMANT CONTAINING SAID NUCLEIC ACID, METHOD OF PRODUCING SAID MUTANT NITRILE HYDRATASE AND METHOD OF PRODUCING AMIDE COMPOUND | 2017 |
|
RU2736086C1 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| VERSION FC AND ITS PRODUCTION | 2021 |
|
RU2828852C1 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
